Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew R Rezvani

Showing results (21-30 of 63) with videos related to

Pageof 7
Sort By:
Blood|January 12, 2012
The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantationBart L Scott, Ted A Gooley, Mohamed L Sorror, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2007
Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphomaAndrew R Rezvani, Barry Storer, Michael Maris, et al.
Transplantation and Cellular Therapy|July 18, 2021
A Fructo-Oligosaccharide Prebiotic Is Well Tolerated in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Dose-Escalation TrialTessa M Andermann, Farnaz Fouladi, Fiona B Tamburini, et al.
Transplantation and Cellular Therapy|April 29, 2021
Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide EraAndrew Johnsrud, Abdullah Ladha, Lori Muffly, et al.
Blood|November 3, 2016
Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCTChristine E Ryan, Bita Sahaf, Aaron C Logan, et al.
British Journal of Haematology|September 2, 2008
Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experienceAndrew R Rezvani, Lalitha Norasetthada, Ted Gooley, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 3, 2014
Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantationRyan D Cassaday, Barry E Storer, Mohamed L Sorror, et al.
Bone Marrow Transplantation|June 24, 2021
Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myelomaChristopher Lemieux, Lori S Muffly, David J Iberri, et al.
Blood|January 21, 2021
Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trialEphraim J Fuchs, Paul V O'Donnell, Mary Eapen, et al.
British Journal of Haematology|February 2, 2022
Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplantMalvi Savani, Kwang W Ahn, Yue Chen, et al.
Pageof 7

Showing results (21-30 of 63) with videos related to

Sort By:
Pageof 7
Blood|January 12, 2012
The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantationBart L Scott, Ted A Gooley, Mohamed L Sorror, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2007
Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphomaAndrew R Rezvani, Barry Storer, Michael Maris, et al.
Transplantation and Cellular Therapy|July 18, 2021
A Fructo-Oligosaccharide Prebiotic Is Well Tolerated in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Dose-Escalation TrialTessa M Andermann, Farnaz Fouladi, Fiona B Tamburini, et al.
Transplantation and Cellular Therapy|April 29, 2021
Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide EraAndrew Johnsrud, Abdullah Ladha, Lori Muffly, et al.
Blood|November 3, 2016
Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCTChristine E Ryan, Bita Sahaf, Aaron C Logan, et al.
British Journal of Haematology|September 2, 2008
Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experienceAndrew R Rezvani, Lalitha Norasetthada, Ted Gooley, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 3, 2014
Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantationRyan D Cassaday, Barry E Storer, Mohamed L Sorror, et al.
Bone Marrow Transplantation|June 24, 2021
Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myelomaChristopher Lemieux, Lori S Muffly, David J Iberri, et al.
Blood|January 21, 2021
Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trialEphraim J Fuchs, Paul V O'Donnell, Mary Eapen, et al.
British Journal of Haematology|February 2, 2022
Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplantMalvi Savani, Kwang W Ahn, Yue Chen, et al.
Pageof 7